Tag: multiple sclerosis

Cautionary Findings on Immunodeficiency From Anti-CD20 MS Therapy

REPORTING FROM AAN 2020 Thirty-eight percent of a large cohort of multiple sclerosis (MS) patients developed low IgM and 7.4% became hypogammaglobulinemic during a mean...

Initial High-Efficacy MS Therapy Tied to Less Disability Later

Starting treatment for relapsing-remitting multiple sclerosis (MS) with high-efficacy therapy (HET) is associated with lower long-term disability compared with a step-wise increase to reach more...

Five-Year Siponimod Data Support Early MS Treatment

Among patients with secondary progressive multiple sclerosis (MS) who received siponimod or placebo during a double-blind trial and entered an open-label extension, those who received...

Joint ACTRIMS/ECTRIMS Conference Still a Go Despite Pandemic

What your doctor is reading on Medscape.com: APRIL 22, 2020 — The show will go on. In some shape or form, organizers of...